All In Biotech

Drug Trial Radar · NCT07709000

A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Nov 16, 2033

Study completion Nov 16, 2033

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.

Conditions

  • Chronic Lymphocytic Leukaemia
  • Small Lymphocytic Lymphoma
  • Hematologic Malignancies

Interventions

  • MK-1045Biological

    Intravenous (IV) infusion

  • Acetaminophen (or similar antipyretic)Drug

    Oral administration as a premedication

  • Diphenhydramine (or similar antihistamine)Drug

    Per approved product label as a premedication

  • DexamethasoneDrug

    IV administration as a premedication

  • TocilizumabBiological

    IV administration as a rescue medication

  • Tocilizumab biosimilarBiological

    IV administration as a rescue medication

  • SiltuximabBiological

    IV administration as a rescue medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A Part 1: Number of Participants Who Experience Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 29 days
  2. Cohort A Part 1: Number of Participants Who Experience an AETime frame: Up to approximately 27 months
  3. Cohort A Part 1: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 24 months
  4. Cohort A Parts 1 and 2: Objective Response Rate (ORR)Time frame: Up to approximately 66 months

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • Hospital Pablo Tobon Uribe ( Site 0601)

    Medellín, Antioquia, Colombia · Recruiting

  • Los Cobos Medical Center ( Site 0607)

    Bogotá, Bogota D.C., Colombia · Recruiting

  • Rambam Health Care Campus ( Site 0803)

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center ( Site 0801)

    Jerusalem, Israel · Recruiting

  • Haddasah Medical Center ( Site 0800)

    Jerusalem, Israel · Recruiting

  • Sheba Medical Center ( Site 0802)

    Ramat Gan, Israel · Recruiting

  • Sourasky Medical Center ( Site 0804)

    Tel Aviv, Israel · Recruiting

  • Hospital General Universitario Gregorio Marañón ( Site 1103)

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre ( Site 1104)

    Madrid, Spain · Recruiting

  • Hospital Clinico Universitario de Salamanca ( Site 1102)

    Salamanca, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.